Author name: clinicspotslocal

Yes, but not with just any GLP-1 drug you’ve heard of. The medications approved for chronic weight management in people without diabetes are specific higher-dose formulations of semaglutide and tirzepatide, built and tested for that exact purpose. They’re not the same product as the diabetes version, even when the molecule shares a name. Dr. Ayush […]

Losing weight with GLP-1 medications such as semaglutide or tirzepatide is a major achievement, but maintaining those results can be challenging. After reaching a target weight, some patients may benefit from a GLP-1 maintenance dose to help manage appetite, reduce the risk of weight regain, and support long-term metabolic health. The right approach varies from

A diabetic foot ulcer is classified into five stages under the Wagner system, Grade 1 through Grade 5. Depth of the wound decides the grade, along with whether infection or gangrene has set in. Grade 1 sits in the skin only. Grade 5 means extensive gangrene across the foot, a very different clinical picture entirely.

Mounjaro is a weekly injection that helps your body control hunger and blood sugar at the same time. It works differently from older weight loss medications because it activates two hormonal pathways instead of one, which makes it more effective for many patients. But here’s what most people don’t realise before starting. Month 1 is

Meditation helps diabetes by lowering stress hormones like cortisol, the same hormones that push blood glucose into sharp spikes. Calm the stress response and the sugar surges that ride along with it tend to settle too. It is not a replacement for insulin or your prescribed medicines, and it never will be. But the research

Continuous glucose monitoring tracks your sugar around the clock. A small sensor sits under the skin, usually on the upper arm, reading glucose every few minutes and sending it straight to your phone. No finger pricks. No guessing in the hours between tests. What you get is the whole day instead of a few scattered

GLP-1 (glucagon-like peptide-1) receptor agonists have shifted the clinical approach to weight management significantly. Originally developed for Type 2 diabetes, these peptide-based medications reduce appetite, slow gastric emptying, and directly influence the brain’s hunger signalling pathways, making them a medically distinct tool for sustained weight loss. According to Dr. Ayush Chandra, a highly experienced SCOPE-certified

Diabetes and hypertension are tightly linked. They share the same roots: insulin resistance, excess weight, and inflammation running through the body. Diabetes scars blood vessels and stiffens them, so fluid backs up. Hypertension narrows the flow and, on its own, raises the odds of diabetes later. One feeds the other. Together they go after the

Type 2 diabetes medications can produce weight loss ranging from 1 to 3 kg with Metformin to over 20 percent body weight reduction with newer dual incretin agents. Around 80 to 90 percent of Type 2 diabetic patients carry excess weight, making drug class selection critical for long-term outcomes. According to Dr. Ayush Chandra, an